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Abstract: Nitrile hydratase (NHase), an industrially important enzyme that
catalyzes the hydration of nitriles to their corresponding amides, has only
been characterized from prokaryotic microbes. The putative NHase from the
eukaryotic unicellular choanoflagellate organism Monosiga brevicollis
(MbNHase) was heterologously expressed in Escherichia coli. The resulting
enzyme expressed as a single polypeptide with fused α- and β-subunits linked
by a seventeen-histidine region. Size-exclusion chromatography indicated
that MbNHase exists primarily as an (αβ)2 homodimer in solution, analogous
to the α2β2 homotetramer architecture observed for prokaryotic NHases. The
NHase enzyme contained its full complement of Co(III) and was fully
functional without the co-expression of an activator protein or E. coli
GroES/EL molecular chaperones. The homology model of MbNHase was
developed identifying Cys400, Cys403, and Cys405 as active site ligands. The
results presented here provide the first experimental data for a mature and
active eukaryotic NHase with fused subunits. Since this new member of the
NHase family is expressed from a single gene without the requirement of an
activator protein, it represents an alternative biocatalyst for industrial
syntheses of important amide compounds.
Abbreviations
 NHase, nitrile hydratase;
 ORF, open reading frame;
 ICP-MS, inductively-coupled plasma mass spectrometry;
 IMAC, immobilized metal affinity chromatography
Keywords: Nitrile hydratase, Enzyme kinetics, Cobalt, Hydrolysis

1. Introduction
Nitrile hydratases (NHases, EC 4.2.1.84) catalyze the hydration
of nitriles to their corresponding amides.1,2 Since the currently
employed industrial conditions used to hydrate nitriles to amides
(either acid or base hydration), are often incompatible with the
sensitive structures of many industrially and synthetically relevant
compounds, NHases have attracted substantial interest as biocatalysts
in preparative organic chemistry. For example, acrylonitrile and
adiponitrile are used in the production of polyacrylamide and nylon-66,
respectively, the latter of which is one of the most important industrial
polyamides.3 Nitriles are also often used as synthetic starting materials
since they add an extra carbon atom to an alkyl chain. Since nitriles
are synthesized by plants, fungi, bacteria, algae, insects and sponges,
there are several biochemical pathways for nitrile degradation.4
Enzymes involved in nitrile degradation pathways represent chemoselective biocatalysts capable of hydrating nitriles under physiological
reaction conditions.4,5
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X-ray crystallographic studies on bacterially-encoded NHases
have revealed that they are α2β2 heterotetramers with an active site in
each α subunit consisting of three cysteine residues, two backbone
amide nitrogen's, a water molecule, and either an Fe(III) ion (Fe-type)
or a Co(III) ion (Co-type).2 Two of the active site cysteine residues
are post-translationally modified to cysteine-sulfinic acid (− SO2H) and
cysteine-sulfenic acid (− SOH), respectively, yielding an unusual metal
coordination geometry, termed a “claw-setting”. Oxidation of the
equatorial Cys residues is critical for catalysis.6 Although the structures
of Fe- and Co-type NHases are very similar, Fe-type NHases only bind
Fe(III) and Co-type NHases only bind Co(III). This specificity is
thought to be regulated by one of several open reading frames (ORFs),
that encodes for an activator protein that has been identified just
downstream from the structural α- and β-subunit genes in NHases.7,8,9
Even though Co- and Fe-type NHase enzymes share high sequence
identity, their respective activator proteins are different in size
(~ 14 kDa for Co-type vs. ~ 47 kDa for Fe-type NHase) and share
little or no sequence identity.10,11 The prevailing dogma is that both
Co- and Fe-type NHase enzymes require the co-expression of an
activator protein to be soluble and fully active.7,8,9 The exception is the
Fe-type NHase from Comamonas testosteroni Ni1 (CtNHase), which
was shown to be functionally expressed without the co-expression of
an activator protein.12
Until recently, NHases have only been found in prokaryotes;
however, a novel gene that contains putative NHase α- and β-subunits
was reported in several unicellular eukaryotic organisms such as
Monosiga brevicollis, Thecamonas trahens, Sphaeroforma arctica,
Stephanoeca diplocostata, Salpingoeca rosetta, Emiliania huxleyi and
Aureococcus anophagefferens.13,14 Unlike prokaryotic NHases, the
putative eukaryotic NHase ORF contains fused α- and β-subunits
bridged by an insert that codes for multiple but variable numbers of
His residues (Fig. 1). For example, the M. brevicollis gene encodes
(His)17, while the gene from S. rosetta encodes only (His)2.13,14 The Cterminus of the eukaryotic holo-protein contains the strictly conserved
metal-binding motif (CTLCSCY) found in the α-subunit of Co-type
NHases and the homologous cobalt-containing thiocyanate hydrolase.15
Interestingly, no gene encoding an activator protein was identified.
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Fig. 1. Alignment of the amino acid sequence of the eukaryotic NHase from
M. brevicollis and prokaryotic nitrile hydratases. A) Amino acid alignment of
the N-terminus residues of the eukaryotic NHase from M. brevicollis and
prokaryotic NHase β-subunits. B) Amino acid alignment of the C-terminus
residues of the eukaryotic NHase from M. brevicollis and prokaryotic NHase αsubunits. Conserved residues among MbNHase and prokaryotic NHases are
highlighted in black and gray. The metal-binding motif is highlighted in cyan
and active site Co-type NHase residues are in orange. The histidine-rich
region is highlighted in light yellow. MbNHase from M. brevicollis; Co-NHases:
PtNHase (Pseudonocardia thermophila JCM 3095), Rh_LM, (low-molecular
weight, Rhodococcus rhodochrous J1), Rh_HM (high-molecular weight,
Rhodococcus rhodochrous J1); Iron-NHases: Rh_N-771 (Rhodococcus sp. N771), Ct (Comamonas testosteroni Ni1), Re (Rhodococcus equi TG328-2);
SCN_alpha, SCN_beta, and SCN_gamma, cobalt thiocyanate hydrolase
(SCNase) from Thiobacillus thioparus THI115.

As no eukaryotic NHase enzyme has yet been described, we set
out to determine whether the putative NHase gene from M. brevicollis
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does indeed code for a functional NHase. The gene encoding the fused
α- and β-subunits of the hypothetical NHase from M. brevicollis was
heterologously expressed in E. coli. The resulting enzyme contained its
full complement of Co(III) and was a fully functional NHase, all without
the co-expression of an activator protein or E. coli GroES/EL molecular
chaperones. This is the first report of a eukaryotic NHase and because
this new member of the NHase family is expressed from a single gene
without the requirement of an activator protein, it represents an
alternative biocatalyst for industrial syntheses of important amide
compounds.

2. Materials and methods
2.1. Materials
Acrylonitrile, Tris-HCl, and HEPES were obtained from SigmaAldrich (St. Louis, MO, USA). All other materials were purchased at the
highest quality available.

2.2. Plasmid construction
Protein sequences for the α- and β-subunit genes of the putative
MbNHase were obtained from ORF 37534 (UniProt ID A9V2C1.1) of M.
brevicollis. The predicted gene was synthesized by Integrated DNA
Technologies, Inc. with optimized E. coli codon usage (SI Fig. 1) and
cloned into the pIDT-SMART kanamycin resistant vector with NdeI and
HindIII restriction sites. The gene was subsequently digested and
ligated into the ampicillin resistant pET21a+ (EMD Biosciences)
expression vector to create the plasmid pSMMαβ. The sequence was
confirmed using automated DNA sequencing at the University of
Chicago Cancer Research Center DNA sequencing facility.

2.3. Expression of recombinant MbNHase in the
absence of an activator protein
The hypothetical MbNHase gene was expressed alone, without
co-expressing a Co-type activator protein or the E. coli chaperones
GroES/EL, in the following manner. The pSMMαβ plasmid was freshly
transformed into E. coli BL21(DE3) competent cells (Agilent
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Technologies) and a single colony was used to inoculate a 50 mL LBMiller culture containing 50 μg/mL of carbenicillin with shaking
overnight at 37 °C. This culture (~ 7 mL) was used to inoculate a 1 L
culture containing 100 μg/mL of ampicillin and the cells were grown at
37 °C until the OD600 nm reached 0.8–1.0. The culture was cooled on
ice to 20 °C, induced with 0.1 mM isopropyl β-D-1thiogalactopyranoside (IPTG) in the presence of 0.25 mM CoCl2 and
expressed at 20 °C for 16 h. Cells were harvested by centrifugation at
6370 × g for 10 min at 4 °C in a Beckman Coulter Avanti JA-10 rotor.
Cell pellets were resuspended in buffer A (50 mM NaH2PO4 pH 8.0,
500 mM NaCl, and 10 mM imidazole with 5% glycerol) at a ratio of
5 mL per gram of cells, then sonicated for 4 min (30 s on 45 s off) at
21 W using a Misonix sonicator 3000. The crude extract was obtained
after centrifugation in a JA-20 rotor at 31,000 × g and 4 °C for
20 min. The sample was subjected to another round of centrifugation
before purification to remove particulate matter.

2.4. Purification of recombinant MbNHase
Crude extracts of MbNHase were loaded onto a 5 mL Ni(II)nitrilotriacetic acid (NTA) Superflow Cartridge (Qiagen) for immobilized
metal affinity chromatography (IMAC) using an ÄKTA FPLC P-960
column. The column was washed with four column volumes (CVs) of
buffer A (50 mM NaH2PO4 pH 8.0, 500 mM NaCl, and 35 mM
imidazole) followed by washes with 50 mM HEPES pH 8.0, 500 mM
NaCl containing 60 mM and 110 mM imidazole, respectively. The
protein was eluted with a linear gradient (0–100%) of buffer B (50 mM
HEPES pH 8.0, 500 mM NaCl with 500 mM imidazole) over 20 CVs at a
flow rate of 1 mL/min. Active protein fractions were pooled and
concentrated with an Amicon Ultra-15 10,000 MWCO centrifugal filter
unit (Millipore) resulting in ~ 10 mg/L of culture containing soluble
MbNHase. Size-exclusion chromatography was used to remove
remaining impurities and to assess the quaternary structure of
MbNHase (Fig. SI-2). A 16/60 Superdex 200 prep grade (GE
Healthcare) column was calibrated from 12.4 to 200 kDa using the
MWGF200 gel filtration calibration kit (Sigma). Purified protein samples
were analyzed by SDS-PAGE with a 12.5% polyacrylamide SPRINT
NEXT GEL™ (Amresco). Gels were stained with Gel Code Blue
(Thermo-Fisher Scientific). Protein concentration of purified protein
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was determined using either a Coomassie (Bradford) Protein Assay Kit
(Pierce) or by measuring the absorbance at 280 nm on a Shimadzu
UV-2450 spectrophotometer. Theoretical molecular weights and
protein extinction coefficients were calculated with the ExPASy
compute pI/Mw tool.16 The molecular weight for the MbNHase
homodimer was 111,207 g/mol with an extinction coefficient of
143,700 cm− 1 M− 1. The molecular weight is in good agreement with
SDS-PAGE data.

2.5. Kinetic analysis of MbNHase
The enzymatic activity of MbNHase towards acrylonitrile
(acrylamide; Δε225 = 2.9 mM− 1 cm− 1) and benzonitrile (benzamide;
Δε242 = 5.5 mM− 1 cm− 1), was measured using a Shimadzu UV-2450
spectrophotometer. A 1 mL reaction consisted of 50 mM Tris-HCl
buffer pH 7.0 at 25 °C and various concentrations of acrylonitrile or
benzonitrile.17 Data analysis was performed using OriginPro 9.0
(OriginLab, Northampton, MA). The kinetic constants Vmax and Km
(were calculated by fitting the data to the Michaelis and Menten
equation. One unit of enzyme activity was defined as the amount of
enzyme that catalyzed the production of 1 μmol of the amide per
minute at 25 °C.

2.6. Metal analysis
The metal content of purified protein was determined by
inductively-coupled plasma mass spectrometry (ICP-MS). Purified
MbNHase (1 mg) expressed in the presence and absence of added
CoCl2. For comparison purposes, the Co-type NHase from
Pseudonocardia thermophila JCM 3095 (PtNHase) (1 mg) was
expressed and purified as previously described,18 and examined along
with a control of buffer containing no protein. All protein samples were
digested with concentrated nitric acid (0.863 mL) and heated at 70 °C
for 1 h, allowed to cool to room temperature and then diluted to final
concentration of 5% nitric acid. Samples were submitted for analysis
at the Water Quality Center in the College of Engineering at Marquette
University (Milwaukee, WI, USA).
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2.7. Electronic absorption spectra
Electronic absorption spectra were recorded on a Shimadzu UV2600 spectrophotometer equipped with a TCC-240A temperature
controlled cell holder. Spectra of MbNHase and PtNHase were obtained
at 25 °C in a 1 cm quartz cuvette in 50 mM HEPES buffer containing
300 mM NaCl, pH 8.0, for MbNHase or pH 7.5 for PtNHase.

2.8. Homology model of the MbNHase
A homology model of the MbNHase was developed using the Xray crystal structure of PtNHase (PDB code:1IRE) as a template.19,20
Sequence analysis of the target and template α- and β-subunits only,
revealed that these proteins are of similar length, with a sequence
identity of 29%, and exhibit no significant sequence gaps. The YASARA
homology-building program was used to construct the structural
homology model of MbNHase.21,22 Comparison of the energy minimized
MbNHase α- and β-subunit homology model to the X-ray crystal
structure of PtNHase, using the MatchMaker in UCSF Chimera, reveals
that the MbNHase α- and β-subunit homology model displays the
typical dimerization and catalytic domains of PtNHase with a
Needleman-Wunsch23 score of 285 and an average RMSD of 1.129 Å
over the aligned 354 Cα atom pairs.

3. Results and discussion
3.1. Sequence alignment of MbNHase with prokaryotic
NHases
The predicted NHase polypeptide encoded by the M. brevicollis
ORF 37534 contains 495 amino acids.14 The first ~ 240 AA of the Nterminus of this putative NHase align with the β-subunit of prokaryotic
NHases (Fig. 1A), while the last ~ 240 AA of the C-terminus aligns
with, and has high similarity (35–45%) with prokaryotic NHase αsubunits (Fig. 1A). The α- and β-subunit regions in MbNHase are
connected by a histidine rich region containing seventeen histidine
residues while the C-terminus region contains the signature NHase
metal-binding domain of Co-type NHases (Fig. 1B).
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3.2. Characteristics of purified MbNHase
MbNHase was expressed in E. coli without the co-expression of
the E. coli molecular chaperones GroES/EL or an activator protein. The
protein was purified by IMAC using the seventeen His residues
naturally encoded in the insert between the α- and β-subunit regions
as the tag, providing ~ 10 mg/L of soluble protein. SDS-PAGE analysis
revealed a band with molecular weight of ~ 55 kDa (Fig. 2A), which is
in good agreement with the theoretical molecular weight of 55.6 kDa.
A faint second band is also observed at ~ 110 kDa, which is consistent
with a small fraction of MbNHase homodimer (111.2 kDa) that was not
fully denatured under the conditions used. In contrast to prokaryotic
NHases, MbNHase is expressed as a fused protein where both the αand β-subunits reside in a single polypeptide as predicted by Foerstner
et al.14 Even though this is the first example of a fused eukaryotic
NHase, the expression of a subunit-fused bacterial NHase from
Pseudomonas putida24 has also been reported, however, in this case
the subunit-fusion was accomplished by engineering a proline-glycine
dipeptide linker between the two subunit genes by PCR. Size-exclusion
chromatography indicated that MbNHase exists primarily as an (αβ)2
homodimer in solution, analogous to the α2β2 homotetramer
architecture observed for prokaryotic NHases, with a small fraction
(< 10%) present as a monomer (Fig. SI-2).

3.3. Kinetic characterization of MbNHase
Kinetic analysis revealed that MbNHase expressed in the
presence of 0.25 mM CoCl2 is capable of hydrating acrylonitrile, the
standard substrate for NHase kinetic analysis, with a kcat of
130 ± 3 s− 1 and a Km of 78 ± 3 mM, providing a catalytic efficiency
kcat/Km of 1.7 s− 1 mM− 1. Since the turnover rate is in line with other
reported Co-type NHase enzymes (kcat = 50 to 1500 s− 1),2,18 it was
hypothesized that the metal ion was properly inserted and that both
active site Cys residues (Cys403 and Cys405) were properly oxidized
in the absence of an activator protein, which is typically required for
full NHase enzymatic activity.7,8,9 MbNHase is also capable of hydrating
benzonitrile with kcat of 33 ± 1 s− 1 and a Km = 18 ± 1 mM, providing a
catalytic efficiency kcat/Km of 1.8 s− 1 mM− 1. These data suggest that
MbNHase exhibits a higher affinity for aromatic nitrile substrates
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compared to aliphatic substrates, following the trend observed for
most Co-type NHases.4,15

3.4. Metal analysis and spectral characterization of
MbNHase
A combination of UV–Vis spectroscopy and metal analysis was
used to determine if MbNHase expressed in the absence of an activator
protein contained its full complement of Co(III). After purification,
MbNHase expressed in the presence of 0.25 mM CoCl2 exhibits the
characteristic amber color of a Co-type NHase enzymes (Fig. 2B,
inset).2 ICP-MS data indicate that MbNHase expressed in the presence
of 0.25 mM CoCl2 contained ~ 1.8 equivalents of cobalt per
homodimer while MbNHase expressed in the absence of CoCl2
contained 1.6 cobalt ions per homodimer. The UV–Vis spectrum of
MbNHase expressed in the presence and absence of cobalt shows the
characteristic S → Fe(III) ligand-to-metal-charge-transfer (LMCT) band
at ~ 320 nm (ε = 19,392 M− 1 cm− 1) (Fig. 2B).2 These data show that
MbNHase contains its full complement of Co(III) and can thus be
expressed in E. coli in the absence of a Co-type NHase activator
protein or the E. coli molecular chaperones GroES/EL. Given the high
iron content of LB media, these data also suggest that the MbNHase
has high affinity for cobalt and can be classified as a Co-type NHase.
All Fe- and Co-type NHase enzymes reported to date require the
co-expression of an activator protein for metal ion insertion and the
post-translational oxidation of the two equatorial active site cysteine
residues.11,25 The only exception is CtNHase.12 For M. brevicollis, no
ORF encoding for an NHase activator or accessory protein, which is
usually found downstream of the prokaryotic NHase genes, has been
reported.13,14 Based on the binding ability of MbNHase during
purification to the Ni-NTA column material, even though no His-tag
was engineered, it is clear that the histidine-rich region found in the
insert between the β- and α-subunits of MbNHase is capable of tight,
but reversible binding of divalent transition metal ions. It is tempting,
then, to speculate that the histidine-rich insert plays a role similar to
that of the activator protein in metal acquisition and/or insertion.
Histidine rich regions are present in some proteins of the cobalamin
(vitamin B12) biosynthetic pathway, e.g., the chelatase CbiX enzyme
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from Bacillus megaterium and CobW from Pseudomonas
denitrificans.26 Histidine rich regions are also found in
metallochaperone and accessory proteins involved in metallocenter
assembly of nickel hydrogenases and ureases, such as HypB from
Bradyrhizobium japonicum and Rhizobium leguminosarum, SlyD from
Escherichia coli and Helicobacter pylori, UreE from Klebsiella
aerogenes, Hpn and Hpn-like proteins from Helicobacter pylori.27
Based on the similarity of the histidine rich region with accessory
proteins involved in the metallocenter assembly of cobalamin,
hydrogenases, and ureases, it is possible that the histidine rich insert
that links the β- and α-subunits of MbNHase, and those found in other
eukaryotic NHases, play a role in cobalt binding and possible insertion
of the cobalt ion into the active site.

3.5. Homology model of MbNHase
Since no three-dimensional X-ray crystal structure exists for
MbNHase, a homology model was developed using the X-ray crystal
structure of the prototypical prokaryotic Co-type NHase from
Pseudonocardia thermophila JCM 3095 (PtNHase; PDB code: 1IRE) as
a template (Fig. 3A). Only the α- and β-subunits of MbNHase were
modeled as no suitable template structure exists for the entire
MbNHase peptide. The α- and β-subunit model of MbNHase suggests
that it is, in general, structurally similar to other Co-type NHase
enzymes ( Fig. 3A). The α-subunit of MbNHase is embedded in the
center of the β-subunit, while the N-terminus of the α-subunit forms a
helix that is embedded among three helices from the β-subunit. The
model reveals that within 4.0 Å of the Co(III) binding site, all of the
amino acid residues are identical to those in PtNHase. The Co(III) ion
of MbNHase is five coordinate and bound by C400, C403, and C405 as
well as two backbone amide nitrogen's, where C403 and C405 are both
modeled as oxidized cysteine-sulfinic and cysteine-sulfenic acids,
respectively ( Fig. 3B). The oxidation of the equatorial Cys residues is
expected since MbNHase exhibits nitrile hydratase activity and
oxidation of the equatorial Cys residues is required for catalytic
activity.6 Two amide nitrogen atoms and the oxidized sulfur atoms are
roughly in the same plane as the metal ion. The sulfur atom from C400
forms a coordination bond roughly perpendicular to this plane, which
results in a slightly distorted square-based pyramidal geometry. On
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the opposite side of C400, no sixth ligand such as water was modeled
but is often observed for Co-type NHase enzymes.2 The sulfinic and
sulfenic acid ligands are within hydrogen bonding distance of two
strictly conserved and catalytically important β-Arg56 and β-Arg167
residues found in Co-type NHase enzymes. These Arg residues are
conserved in all bacterial NHases and play a role in the stabilization of
the “claw-setting” structure through the hydrogen bonding.

Fig. 3. Homology model of MbNHase. A) The MbNHase homology model for the α- and
β-subunits only are highlighted in blue is overlaid with the X-ray crystal of PtNHase
(PDB code:1IRE) which is in green. B) The active site of MbNHase derived from the
homology model showing the classical “claw-setting” of an NHase.

4. Conclusion
The construct presented here provides the first evidence of a
functional subunit-fused eukaryotic NHase. We found that expression
of MbNHase does not require an NHase activator protein or the E. coli
chaperone proteins GroEL/ES. These data are contrary to the accepted
view regarding the strict requirement of co-expressing NHases with
activator proteins for fully active enzymes. Based on UV–Vis and ICPMS data, MbNHase binds it full complement of Co(III) ions in its active
site and the equatorial Cys residues are appropriately oxidized, which
is a requirement for full enzymatic activity. Both metal ion insertion
and Cys oxidation are functions previously ascribed to NHase activator
Biochimica et Biophysica Acta: Proteins and Proteomics, Vol 1865, No. 1 (January 2017): pg. 107-112. DOI. This article is ©
Elsevier and permission has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from
Elsevier.

12

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

proteins. The homology model suggests that the MbNHase polypeptide
encoding for the α- and β-subunits is capable of folding like a
prototypical prokaryotic Co-type NHase. The position of the predicted
active site residues of MbNHase align with those of PtNHase including
the highly conserved β-Arg residues in prokaryotic Co-type NHases
that form hydrogen bonds to the active site oxidized Cys residues.28
Both of these β-Arg residues are catalytically important for both Feand Co-type prokaryotic NHase enzymes. Since MbNHase is a new
member of the NHase family that is expressed from a single gene
without the requirement of an activator protein, it represents an
alternative biocatalyst for industrial syntheses of important amide
compounds.
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Appendix A. Supplementary data
Appendix A. Supplementary data
Supplementary information includes DNA and amino acid sequences of
MbNHase (Fig. SI-1), a size-exclusion chromatography elution profile
(Fig. SI-2), and an image of an SDS-PAGE for apo MbNHase (Fig. SI3). Supplementary data associated with this article can be found in the
online version, at doi:
http://dx.doi.org/10.1016/j.bbapap.2016.09.013.
Supplementary Material
Figure SI-1. The DNA sequence encoding the nitrile hydratase from Monosiga
brevicollis was codon-optimized for over-expression in E. coli and synthesized by IDT
(Iowa, USA). The codon-optimized gene and amino acid sequences of MbNHase are
shown below.
1 ATG CAT CTG TTC ACG TAT GAT CTG CAC CAT GAC GTG GGC GGT GCG 45
1 Met His
Leu Phe Thr Tyr Asp Leu His His Asp Val Gly Gly Ala
46 GAA AAC ATG CTT CGT CTG CCG CTG GAT CGT CAC GAA CGT GAT TAC 90
16 Glu Asn Met Leu Arg Leu Pro Leu Asp Arg His Glu Arg Asp

15

Tyr

30

91 CTG CCG TGG GAA CGT CAT ATT CAC GCT TTG GTA GTG TTG CTG GTC 135
31 Leu Pro Trp Glu Arg His Ile His Ala Leu Val Val Leu Leu Val

45

136 AAA CAA GGC CGT ATG AGC GTT GAT GAG TTG CGT CGC GGG GTC GAA 180
46 Lys Gln Gly Arg Met Ser
Val Asp Glu Leu Arg Arg Gly Val Glu

60

181 GGC CTG CCT TCC TCA TTA GCG GAA CAG GCG AGC TAT TAC GAA AAG 225
61 Gly Leu Pro Ser Ser Leu Ala Glu Gln Ala Ser Tyr Tyr Glu Lys
75
226 TGG GGG TTG TCG GTG TCA CGT ATT CTG ACG GAA AAA GGC ACG GTC 270
76 Trp Gly Leu Ser Val Ser Arg Ile Leu Thr
Glu Lys Gly Thr
Val

90

271 TCA GGT CAC GAA CTG GAG CAA GGG TTC TTA GGT GTT CCG ACG ACG 315
91
Ser Gly His Glu Leu Glu Gln Gly Phe Leu Gly Val Pro Thr Thr

105

316 GAT CTG CCG CAG GTG CCC CGC TTC CAG GTG GGC CAA CGT GTA ATG 360
106 Asp Leu Pro Gln Val Pro Arg Phe Gln Val Gly Gln Arg Val Met

120

361 GTG CGT CCG TTC GGG ACA ACG TTT GCA TAC CGC CAA CCC CAT CTG 405
121 Val Arg Pro Phe Gly Thr Thr Phe Ala Tyr Arg Gln Pro His Leu

135

406 CGT GTT CCG GGG TAT GTT CAT GGA GCC GTG GGC ACT ATC GTG GAA 450
136 Arg Val Pro Gly Tyr Val His Gly Ala Val Gly Thr Ile Val Glu
150
451 CTG CCT GGG CTG TTT CAG GAT CCT ATG ACC GGC GCT TAC GGG GAA 495
151 Leu Pro Gly Leu Phe Gln Asp Pro Met Thr Gly Ala Tyr Gly Glu

165
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496 CGC GGT ACA GCT CAA CCG CTG TAC CGC GTG GCA TTC AGT CAT CGC 540
166 Arg Gly Thr Ala Gln Pro Leu Tyr Arg
Val Ala Phe Ser His Arg

180

541 GCG CTG TGG CCG GAA GGG GCC GCG CAC GCC GAA CCT GGC GAA CTG 585
181 Ala Leu Trp Pro Glu
Gly Ala Ala
His Ala Glu Pro Gly Glu Leu

195

586 GAA GAT GGC GTA GTC GTG GAT GTC AGT CAG CCA TGG TTA GAG GCT 630
196 Glu Asp Gly Val Val Val Asp Val Ser Gln Pro Trp Leu Glu Ala

210

631 TTA TCT GAA GCT GAT TAC GCA CAG CGT CTG GCG ACG CTG CAT CGT 675
211 Leu Ser Glu Ala Asp Tyr Ala Gln Arg Leu Ala
Thr Leu His
Arg

225

676 GTG GCG TTT ACT CCT GAT AGC AAC CCG CCA CAA GCG CAT AAG CAC 720
226 Val Ala
Phe Thr Pro Asp Ser Asn Pro Pro
Gln Ala His Lys His

240

721 CAT CAT CAC CGT CAT CAT CAT GAC CAC CAT CAT CAT CAT CAT CAT
765
241 His His His Arg His His His Asp His His His His His His His

255

766 CAC CAC GCT ATG CAC GCC GAA CAT GAA GCT CAT ACC CAC GAT ACC 810
256 His His Ala Met His Ala Glu His Glu Ala His Thr His Asp Thr

270

811 CGT TAC GGC ACC GAA CAG GCC GCG GTA GCG AAG GAA GCG GCA TTG 855
271 Arg Tyr Gly Thr Glu Gln Ala Ala
Val Ala Lys Glu Ala Ala
Leu 285
856 GAT TTC CCG TAT CAG CCC TGG TGT GAA GCT CTG GTC CAG ACT CTT 900
286 Asp Phe Pro Tyr Gln Pro Trp Cys Glu Ala Leu Val Gln Thr Leu

300

901 ACC CGC CGC GGG GTC GTG CGC TCG GAC GAG CTG CAT GCT ACG CTG 945
301 Thr Arg Arg Gly Val Val Arg Ser Asp Glu Leu His Ala Thr
Leu

315

946 GCA TCT CTG GAT GCA CTG CAA AAC TCA GGC GCA GGG CCT CAG CTG 990
316 Ala Ser Leu Asp Ala Leu Gln Asn Ser Gly Ala Gly Pro Gln Leu 330
991 GTG GCG CGC GCC TGG TCC GAT GCT GCT TTC GCG GAG TGG TTA CTG 1035
331 Val Ala Arg Ala
Trp Ser Asp Ala Ala
Phe Ala Glu Trp Leu Leu
1036 ACC GAT GCC GCT GCG GCG GCA GAG AGC TTA GCA ATC CGC ACC ACG 1080
346 Thr Asp Ala Ala Ala Ala Ala Glu Ser
Leu Ala Ile
Arg Thr Thr

345

360

1081 AAT TAC GAC GCG GAT CCG GCC TCT GCC GAG CGT GTG GGC GGC CAT 1125
361 Asn Tyr Asp Ala Asp Pro Ala Ser Ala Glu Arg Val Gly Gly His 375
1126 CGC CTG TTT TCG CAC AAT CAT ACG GAA TTA CGT GTC GTT GCG AAC 1170
376 Arg Leu Phe Ser His Asn His Thr Glu Leu Arg Val Val Ala Asn 390
1171 ACC GAC ACC GTA CAT AAC TTA GTA TGC TGC ACG CTG TGT TCT TGT 1215
391 Thr Asp Thr Val His Asn Leu Val Cys Cys Thr
Leu Cys Ser
1216 TAC CCG ACC GCG ATC TTA GGG CTT AGT CCA CCG TGG TAT AAG TCA 1260
406 Tyr Pro Thr Ala Ile
Leu Gly
Leu Ser Pro Pro Trp Tyr Lys

Cys

Ser

1261 AAA GTG TTC CGC GCG CGT GCG GTC CGC GAA CCG CGT CGC TTG CTG 1305
421 Lys Val Phe Arg Ala Arg Ala Val Arg Glu Pro Arg Arg Leu Leu

405

420

435
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1306 CGT GAA GAA TTT GGC CTG GTG TTA CCG GAA GCG CGT GGT ATT CGT 1350
436 Arg Glu Glu Phe Gly Leu Val Leu Pro Glu Ala Arg Gly Ile Arg
1351 GTT CAT GAT AGC ACT GCA GAT CTG CGT TAC ATG GTT CTG CCC CAA 1395
451 Val His Asp Ser Thr Ala Asp Leu Arg Tyr Met Val Leu Pro Gln
1396 CGC CCG CAA GGC ACA GAA GGC TGG TCT GAG GAA CAT CTG CGT ACC 1440
466 Arg Pro Gln Gly Thr Glu Gly
Trp Ser Glu Glu His Leu Arg
1441 ATC GTT ACC CGC GAT AGC CTT CTC GGT ACC GCG GTG CCG CGC GTG 1485
481 Ile
Val Thr Arg Asp Ser Leu Leu Gly Thr Ala Val Pro Arg Val
1486 GAT TAA
496 Asp End

Thr

450

465

480

495

1491
497
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Figure SI-2. Gel filtration elution profile of MbNHase for the determination of the
quaternary structure in solution and molecular mass. Marker proteins used for gel
filtration: (i) cytochrome c, 12.4 kDa, (ii) carbonic anhydrase, 29 kDa, (iii) albumin 66
kDa, (iv) alcohol dehydrogenase, 150 kDa, and (v) beta-amylase, 200 kDa. Peaks at
75.54 mL and 85.10 mL correspond to dimer and monomer of MbNHase, respectively.
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Figure SI-3.
SDS-PAGE analysis of apo-MbNHase: lane 1 molecular weight
standards, lane 2 purified apo MbNHase.
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